Our website is currently being updated and you may experience some limited functionality at this time.

ProAxsis announces it has entered into an exclusive licensing agreement with AstraZeneca and will complete the validation and global commercialization of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA test. In AstraZeneca will provide access to intellectual property and technical know-how, and in return will receive an undisclosed royalty fee on future Global net sales of the assay.

Recent Posts

Share This :